"A REVIEW ARTICLE ON PHARMACOECONOMIC EVALUATION "

P.T. NAGARAJU,*B.V.RAMANA",P.B.INDU.*

K.V.SUBBAREDDY INSTITUTE OF PHARMACY

[i]Dupadu,kurnool,AP-518218

EMAIL ID:indhureddy585@gamail.com

1.**Abstact**:

Pharmacoeconomic evaluation is the assessment of the cost-effectiveness, cost-utility, or cost-benefit of pharmaceutical interventions, aiming to optimize the allocation of healthcare resources. It plays a crucial role in decision-making processes by comparing the costs and health outcomes of different therapeutic options. Pharmacoeconomic studies provide insights into the value of new drugs or treatment strategies in comparison to existing alternatives, enabling healthcare policymakers, providers, and patients to make informed choices.

These evaluations are typically categorized into four main types: cost-effectiveness analysis (CEA), cost-utility analysis (CUA), cost-benefit analysis (CBA), and cost-minimization analysis (CMA). CEA compares the costs and health outcomes (often measured in quality-adjusted life years, or QALYs) between competing interventions. CUA specifically incorporates quality of life in its analysis, giving weight to both the quantity and quality of life gained. CBA, in contrast, assigns monetary value to both the costs and the health outcomes. CMA is used when two or more interventions are equivalent in terms of outcomes, with the primary comparison being the cost.

In addition to these traditional methods, pharmacoeconomics also incorporates sensitivity analysis to account for uncertainty in the assumptions and data used. It helps in identifying the most cost-effective treatment options, particularly when resources are limited. Ultimately, pharmacoeconomic evaluations guide the development of healthcare policies, reimbursement decisions, and patient care strategies, ensuring that the maximum benefit is achieved from the available healthcare budgets. This is especially relevant in the context of rising healthcare costs and the growing burden of chronic diseases globally.

Key words: Pharmacoeconomics, cost effective analysis, cost utility analysis, cost benefit analysis, health care decision making, economic evaluation.

2.Introduction

Similar to other EU nations, Romania experiences increasing pharmaceutical spending caused by increased demand for contemporary healthcare, multinational supplier influence, and population treatment necessities. In spite of cost-containment measures (drug import price regulation, pharmacy margin bargaining, reference pricing), policies have not managed to limit spending, illustrating the necessity for more rigorous assessment methods like pharmacoeconomics.

3.Historical Perspective

Pharmacoeconomics developed during the 1970s as a branch of clinical pharmacy and pharmacokinetics:

1978: McGhan, Rowland, and Bootman suggested cost-effectiveness studies.

1979: Bootman et al. used cost–benefit analysis to individualize aminoglycoside dosages.

1986: Townsend formally brought in "pharmacoeconomics" into academic literature.

It has spread worldwide since then, with an emphasis on combining health, economic, and patient outcomes into drug assessment.

4.Definition of Pharmacoeconomics

Pharmacoeconomics is the use of economic analysis tools on healthcare treatments that involve pharmaceuticals. It is based on comparing costs and consequences among medical options.

It aims to:

Use strict criteria for economic assessment of treatments.

Augment clinical trial data with costing information.

Measure patient quality of life by estimating years saved (QALY) and utility.

Establish cost-derived treatment algorithms and guidelines.

5.Scope and Need

Medicine costs are rising because:

Increased life expectancy, improving standards of living, and the need for expensive therapies.

Excessive medical spending usually compels low-income area patients to make treatment a choice between basic needs.

6.Pharmacoeconomics assists:

Pharmaceutical companies in making R&D investment decisions.

Governments develop reimbursement and cost-control policies.

Insurers define benefit coverage.

Healthcare institutions make rational resource allocation and therapy choices.

Application in Healthcare Practice

Pharmacoeconomics solidifies drug therapy decisions by correlating clinical, financial, and humanistic consequences.

7.Applications are:

Formulary management (inclusion/exclusion of drugs).

Policy development on efficiency and rational use of drugs.

Hospital resource allocation and avoidance of overprescribing.

Assistance in cost-effectiveness in Phase III clinical trials and post-marketing surveillance.

Pharmacoeconomic evaluation integrates costs and benefits.

8.Costs:

Direct costs: drug cost, medical care, and adverse event handling.

Indirect costs: loss of productivity, travel, and caregiver time.

Intangible costs: patient misery, psychological toll.



9.Outcomes:

Natural units: life-years gained, strokes avoided, ulcers cured.

Utility units: Quality-Adjusted Life Years (QALYs).

Humanistic outcomes: patient comfort, satisfaction, functionality.

10.Economic Evaluation Methods

11.Cost Minimisation Analysis (CMA):

Compares costs of alternatives with equivalent outcomes.

Cost-Effectiveness Analysis (CEA):

Quantifies outcomes in clinical units e.g., life-years gained; presented as the Incremental Cost-Effectiveness Ratio (ICER).

Cost-Utility Analysis (CUA): Applies QALYs to balance life quality and quantity.

Cost Benefit Analysis (CBA): Both costs and results are quantified in dollars; leads to the Benefit-to-Cost (B:C) ratio.



FIG 1: COMPONENTS OF PHARMACOECONOMICS

12.Pharmacoeconomics in Drug Development

Pharmacoeconomic research is incorporated into clinical trial stages:

Phase I: cost-of-illness analyses.

Phase II: comparisons with comparative treatments, initial cost-effectiveness.

Phase III: prospective pharmacoeconomic studies concomitant with pivotal trials.

Phase IV:post-marketing: real-world effectiveness and cost analysis.

This facilitates timely recognition of cost-saving products and guides payer reimbursement.

13..Views of Analysis

Pharmacoeconomics may be applied from several perspectives:

Patient: out-of-pocket expense, quality of life.

Provider: actual cost of providing care (manpower, facilities, materials).

Payer: direct cost of reimbursement plus presenteeism/absenteeism impacts.

Society: all direct, indirect, and intangible expenditures (most holistic perspective).

14.Limiting Factors

Market demand and aggressive marketing by pharmaceutical firms may distort decisions.

Physicians can prioritize bioavailability or brand effect over economic worth.

Lack of awareness or limited formal training of prescribers.

Difficulty in measuring intangible benefits like pain and anxiety.

Solutions suggested

Associations/hospitals' direct purchase to save supply chain costs.

Open technical bidding from GMP-compliant companies.

Training healthcare professionals and students in pharmacoeconomics.

15.Promoting rational drug prescribing practice.

Pharmacoeconomic evaluation of Biosimilars used in cancer treatment [16]

Biologics have been used in cancer therapy, and as a result, the expense of cancer treatment is a major factor in healthcare expenditures worldwide. Despite their great effectiveness, biologics are very costly.

However, because the cost of treatment has decreased due to the use of biosimilars, patients now have more access to biological therapies. The overall pharmacoeconomic assessment of biosimilars can be influenced by a number of factors, including the safety and effectiveness of biosimilars in contrast to biologic pharmaceuticals, the expenses associated with production and research, safety monitoring, and price policies implemented by government agencies or institutions.

The adoption of biosimilars in the US is contingent upon a number of factors, including pharmacovigilance and safety profiles, cost-effectiveness, and patient and professional education . The availability of a less expensive biosimilar of G-CSF led to a 10%–20% increase in the usage of G-CSF agents in Germany, the Netherlands, and the UK. Additionally, G-CSF was given early in the course of treatment, which led to a shift in its use from a secondary to a primary preventive drug against febrile neutropenia .

Therefore, it may be claimed that biosimilars have the potential to give patients greater access to biologic medications if they are made more inexpensive.

For the efficient use of biosimilars, many nations take pharmacoeconomic factors into account . Guidelines outlining requirements for conducting economic evaluations that must be included in reimbursement claims have been published in numerous countries.

The pharmacoeconomic studies that are most relevant to biosimilars are determined by the characteristics of the reference biologics and biosimilars .

16.References

1.Paveliu S., Aprovizionarea cu medicamente a populatiei - de la contentia costurilor laevaluarea eficacitatii, Eu Ro Comunitatea ,Medicala, septembrie, 2012;

2.McGhan W, Rowland C, Bootman JL. value–gain, and price-effectiveness: methodologies for evaluating innovative pharmaceutical offerings. Am J Hosp Pharm 1978; 35:133-140

3.Bootman JL, Wertheimer A, Zaske D, Rowland C. Individualizing genta- main dosage regimens on burn sufferers with gram-terrible septicemia: a value–advantage evaluation. J Pharm Sci 1979; 68:267–272

4.Townsend RJ. publish advertising and marketing drug research and improvement: an industry scientific pharmacist's perspective. Am J Pharm Educ 1986; 50:480-482. N Arnold R.J.G., Pharmacoeconomics from theory to practice, CRC Press, 2009;

5. Clinical Pharmacy and Therapeutics, Walker R. And Whittlesea C., fourth edition, Churchill Livingstone Elsevier, 2007Pharmacoeconomics by Cooke J.;

6.Bootman J.L., Townsend R.J., McGhan W.F., Principles of pharmacoeconomics, second edition, 1996;

7.Pradelli L., Wertheimer A., Pharmacoeconomics: Principles and Practice, Kindle Edition, 2013

8.Kumar S, Krishnaveni J, Manjula P, Fundamentals of Clinical Pharmacy Practice, Pharma MedPress, 2007, 134-136.

9.Kumar, S. and Baldi, A., 2013. Pharmacoeconomics: Principles, Method Economic Evaluation of Drug Therapies

10.Gattani, S.G., Patil, A.B. and Kushare, S.S., 2009. Pharmacoeconomics: a review. Asian journalof pharmaceutical and clinical research, 2(3), pp.15-26.